Themis Bioscience Reaps Bill Gates' Backed CEPI Funding For Lassa Fever And MERS Vaccines
Executive Summary
Plans to have candidate vaccines ready for testing against infectious diseases during an evolving epidemic have taken a step forward with the announcement of a partnership between CEPI, the global fund supported by governments and philanthropists, and the vaccine-focused European biotech, Themis Bioscience.
You may also be interested in...
Themis CEO: Chikungunya Vaccine Could Be Approved In Two Years
Themis Bioscience CEO says the biotech’s €40m Series D financing will fund pivotal trials for its lead vaccine candidate for chikungunya and advance its oncology franchise.
Finance Watch: Third Rock Raises $770m To Launch Up To 12 New Companies
The VC firm known for its new company formation efforts will launch 10-12 biopharma, device and diagnostic ventures with its fifth fund. Also, EpimAb raises a $74m series B round, three more drug developers join the IPO queue and Amicus leads recent follow-on offerings.
MSF Attacks Vaccines Collaboration Over ‘Toothless’ New Equitable Access Policy
The Coalition for Epidemic Preparedness Innovationhas come under attack from Médecins sans Frontières over its revised equitable vaccines access policy, which the NGO claims has been watered down at the behest of the pharmaceutical industry.